VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $414,000 Investment in Xencor, Inc. $XNCR

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Xencor, Inc. (NASDAQ:XNCR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,600 shares of the biopharmaceutical company’s stock, valued at approximately $414,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its stake in Xencor by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,567 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 1,767 shares during the last quarter. Pinnacle Wealth Planning Services Inc. boosted its stake in shares of Xencor by 31.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 5,804 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 1,373 shares during the last quarter. VestGen Advisors LLC acquired a new stake in shares of Xencor during the 3rd quarter worth about $2,547,000. GAMMA Investing LLC grew its holdings in shares of Xencor by 15.5% during the third quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 572 shares in the last quarter. Finally, WINTON GROUP Ltd grew its holdings in shares of Xencor by 1.5% during the second quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company’s stock worth $1,711,000 after buying an additional 1,534 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Xencor from $20.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, October 27th. Wall Street Zen upgraded shares of Xencor from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research note on Monday, September 21st. Bank of America lifted their target price on shares of Xencor from $20.00 to $26.00 and gave the stock a “neutral” rating in a research note on Monday, September 21st. Finally, Truist Financial boosted their price target on Xencor from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.22.

Xencor Trading Up 5.0%

NASDAQ XNCR opened at $35.75 on Friday. The business’s 50-day moving average price is $26.17 and its 200 day moving average price is $17.46. Xencor, Inc. has a twelve month low of $10.38 and a twelve month high of $36.50. The company has a market capitalization of $2.68 billion, a PE ratio of -22.48 and a beta of 0.78.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.83. Xencor had a negative return on equity of 21.28% and a negative net margin of 58.79%. The company had revenue of $116.52 million during the quarter, compared to analysts’ expectations of $63.00 million. During the same quarter in the previous year, the business earned ($0.08) EPS. The firm’s revenue was up 453.3% on a year-over-year basis. Equities analysts predict that Xencor, Inc. will post -2.85 EPS for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.